US drugmaker Vertex Pharmaceuticals (Nasdaq: VRTX), the current leader in the cystic fibrosis (CF) space, is spending more to maintain its dominance and develop therapies for other diseases.
Vertex has announced a strategic research collaboration focused on the discovery of novel proteins including DNA endonucleases with privately-held US firm Arbor Pharmaceuticals.
The collaboration will advance the development of new gene-editing therapies for cystic fibrosis and four other diseases to be selected later.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze